Literature DB >> 11918650

A summary of spasticity management--a treatment algorithm.

A B Ward1.   

Abstract

The muscle overactivity seen in spasticity results in limb stiffness and muscle spasm, to which there is both a neurogenic and a biomechanical component. Spasticity does not always cause harm and can assist in the rehabilitation process enabling a patient to stand when their limb weakness would not otherwise allow it. When it does cause harm, however, treatment is required. This aims to (i) prevent provocative factors (ii) treat muscle overactivity; and (iii) prevent complications. Untreated, limb contracture, pain and other complications occur and early management can be most effective. Treatment is essentially physical, but, when this is inadequate, pharmacological intervention may be required. A strategy has been devised which shows that the first choice pharmacological treatment of focal spasticity is botulinum toxin. Over the past decade, the choice of treatment has become more ambitious with the establishment of new technologies. Good management now depends on an understanding of their role and application in relation to the needs of individual patients. To this end, a treatment algorithm which covers the salient facts in patient assessment and gives the indications for the range of available treatments, is the best approach. The indications and limitations of the available treatments are discussed, along with their place in the overall management of the patients. The evidence base for much of what is done is not strong and this summary examines the activities of proven value and of consensus view.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918650     DOI: 10.1046/j.1468-1331.2002.0090s1048.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  15 in total

Review 1.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

2.  Shear wave velocity measurement of upper trapezius muscle by color Doppler shear wave imaging.

Authors:  Atsushi Yamamoto; Yoshiki Yamakoshi; Takashi Ohsawa; Hitoshi Shitara; Tsuyoshi Ichinose; Hiroyuki Shiozawa; Tsuyoshi Sasaki; Noritaka Hamano; Yasushi Yuminaka; Kenji Takagishi
Journal:  J Med Ultrason (2001)       Date:  2017-06-28       Impact factor: 1.314

Review 3.  Intrathecal Baclofen Monotherapy and Polyanalgesia for Treating Chronic Pain in Patients with Severe Spasticity.

Authors:  Anuj Marathe; Sameer Allahabadi; Alaa Abd-Elsayed; Michael Saulino; Jonathan M Hagedorn; Vwaire Orhurhu; Jay Karri
Journal:  Curr Pain Headache Rep       Date:  2021-12-11

4.  Serotonin facilitates a persistent calcium current in motoneurons of rats with and without chronic spinal cord injury.

Authors:  X Li; K Murray; P J Harvey; E W Ballou; D J Bennett
Journal:  J Neurophysiol       Date:  2006-11-01       Impact factor: 2.714

5.  Treatment patterns of in-patient spasticity medication use after traumatic spinal cord injury: a prospective cohort study.

Authors:  Kaila A Holtz; Elena Szefer; Vanessa K Noonan; Brian K Kwon; Patricia B Mills
Journal:  Spinal Cord       Date:  2018-06-14       Impact factor: 2.772

Review 6.  Spasticity treatment with botulinum toxins.

Authors:  A B Ward
Journal:  J Neural Transm (Vienna)       Date:  2008-04-04       Impact factor: 3.575

7.  Spasticity.

Authors:  Allison Brashear; Kelly Lambeth
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

8.  Early predictors of developing problematic spasticity following traumatic spinal cord injury: A prospective cohort study.

Authors:  Patricia B Mills; Kaila A Holtz; Elena Szefer; Vanessa K Noonan; Brian K Kwon
Journal:  J Spinal Cord Med       Date:  2018-10-09       Impact factor: 1.985

9.  Obturator neurolysis using 65% alcohol for adductor muscle spasticity.

Authors:  Anju Ghai; Sukhbir Singh Sangwan; Sarla Hooda; Shashi Kiran; Nidhi Garg
Journal:  Saudi J Anaesth       Date:  2012-07

10.  Consequences of neurologic lesions assessed by Barthel Index after Botox(®) injection may be underestimated.

Authors:  Y Dionyssiotis; D Kiourtidis; A Karvouni; A Kaliontzoglou; I Kliafas
Journal:  Ther Clin Risk Manag       Date:  2012-10-19       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.